Physician Views: What impact from ESMO updates for Keytruda, Kisqali in breast cancer?

Headline clinical data readouts from the ESMO congress this weekend included notable updates for Merck & Co.’s immunotherapy Keytruda in first-line metastatic triple negative breast cancer (TNBC) and Novartis’ CDK4/6 inhibitor Kisqali in first-line advanced HR+/HER2-negative breast cancer.

In both cases first-in-class overall survival data was presented though the competitive landscape for these two agents in these settings is notably different. Whilst Keytruda looks poised to dominate the first-line TNBC market in the near term, Kisqali is looking to make ground on two other CDK4/6 inhibitors which are prescribed more frequently – Pfizer’s Ibrance and Eli Lilly’s Verzenio.

Our latest Physician Views snap poll, fielded to oncologists in the US and Europe, seeks further insight on what impact new data from the Keynote-355 and MONALESSA-2 studies could have on treatment practice.

Results and analysis will be published as soon as possible for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here.

To read more Physician Views articles, click here.